Addiction Medicine Journal Club

Quick summaries of Episodes 31-40. 31. Injection Drug Use Frequency Before and After Take-Home Naloxone Training 32. Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial 33. Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using

In this episode we discuss drug overdose after benzodiazepine prescriptions for anxiety and depression. Bushnell GA, et al. Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals. Addiction. 2023. We also talk about the war on recovery treatments and patients leaving the hospital against medical a

In this episode we discuss improvements in cognitive function with opioid abstinence. Kaur, G. Et Al. Effects of Abstinence From Opioid on Neuropsychological Performance in Men With Opioid Use Disorder: A Longitudinal Study. Journal of Addiction Medicine 17(5): p 557-562, 9/10 2023. We also talk about paramedics giving buprenorphine along with naloxone in the field, and the post-

Articles that Changed Our Practice-Part 2 In this episode we discuss 5 more articles that changed our addiction medicine practice. Chambers LC, et al. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Netw Open. 2023; 6(9):e2334540. September 2023. (Episode 34) Caponnetto, P., et al. Varenicline and counseling for

Articles that Changed Our Practice-Part 1 In this episode we discuss 5 articles that changed our addiction medicine practice. Mahdi Sheikh, et al. Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study. Ann Intern Med.2021;174:1232-1239. [Epub 27 July 2021]. (Episode 4) Santos GM, et al. Targeted Oral Naltrexone

In episode 38 we discuss an article comparing different treatments (and no treatment) for opioid use disorder. Robert Heimer, Anne C. Black, Hsiuju Lin, Lauretta E. Grau, David A. Fiellin, Benjamin A. Howell, Kathryn Hawk, Gail D’Onofrio, William C. Becker. Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment in Connecticut, 2016-17. D

37. Injectable Vs. Sublingual Buprenorphine In episode 37 we discuss an article comparing injectable and sublingual buprenorphine. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. Marsden, John et al. eClinicalMedicine,

In episode 36 we discuss an article about the mediators of problematic smartphone use. Christiane Arrivillaga, Caleb J. Hallauer, Christian Montag, Jon D. Elhai. Emotion dysregulation factors associated with problematic smartphone use severity: The mediating role of fear of missing out. Addictive Behaviors. Volume 143. 2023. https://doi.org/10.1016/j.addbeh.2023.107708 We also disc

In episode 35 we discuss whether eliminating prior auths leads to more buprenorphine prescribing. Christine PJ, Larochelle MR, Lin L, McBride J, Tipirneni R. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder. JAMA Health Forum. 2023;4(10):e233549. We also discuss buprenorphine diversion, and the lack of treatments f

In episode 24 we discuss prescribing 24 mg of buprenorphine daily. Chambers LC, Hallowell BD, Zullo AR, et al. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Netw Open. 2023;6(9):e2334540. September 2023. We also discuss why Rite Aid filed for bankruptcy, and the FDA ban on menthol cigarettes. From the NY Times: R